Crispr Therapeutics AG (CRSP) Stock Price Today
Aura AI Summary
Key Stats
- $5.07BMarket Cap
- -Volume
- HealthSector
- $76.7852W High
- $44.3452W Low
- -Typical Hold Time
- $3.49BEnterprise Value
- -Div Yield
- -Trading Activity
Track Crispr Therapeutics AG (CRSP) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Crispr Therapeutics AG has traded between a low of $44.34 and a high of $76.78, highlighting its annual price range. Buy and sell Crispr Therapeutics AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Most Recent News
Euronext reports July 2026 trading volumes across European markets.
Euronext announced its trading volumes for July 2026, covering multiple European exchanges including Amsterdam, Paris, Milan, and others. The update reflects Euronext's role as a leading capital market infrastructure in Europe, hosting over 1,800 lis...

Thomson Reuters beats Q2 earnings estimates, boosts AI focus and shareholder returns.
Thomson Reuters reported stronger-than-expected Q2 2026 earnings of $0.99 per share, surpassing analyst estimates by 3.13%, with revenues growing 9% to $1.95 billion. The company increased its revenue targets and returned significant capital to share...

HubSpot's Chief Legal Officer sells 728 shares to cover tax withholding.
HubSpot's Chief Legal Officer recently sold 728 shares of the company's stock. The sale was conducted specifically to cover tax withholding obligations. This is a routine transaction often seen when employees or executives receive stock-based compens...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.